Beta-hexosaminidase A (Hex A)

Beta-hexosaminidase A (Hex A) is a vital lysosomal enzyme responsible for the degradation of GM2 gangliosides, which are complex glycosphingolipids essential for neuronal membrane structure. The functional enzyme is a heterodimer composed of an alpha subunit (encoded by the HEXA gene) and a beta subunit (encoded by the HEXB gene). A deficiency in Hex A activity leads to the toxic accumulation of GM2 gangliosides within the lysosomes of neurons, a hallmark of the neurodegenerative condition known as Tay-Sachs disease. This accumulation triggers progressive cellular damage, leading to loss of motor skills, cognitive decline, and early mortality. Therapeutic strategies targeting Hex A include the use of pharmacological chaperones to stabilize misfolded mutant enzymes, substrate reduction therapies to decrease the biosynthetic load of gangliosides, and emerging gene therapies designed to restore functional enzyme production. A primary challenge in treating Hex A-related disorders is the requirement for therapeutic agents to effectively cross the blood-brain barrier to reach the central nervous system.

Other names

Hexosaminidase ABeta-N-acetylhexosaminidase AN-acetyl-beta-glucosaminidaseBeta-hexosaminidase subunit alpha (part of complex)HEXA

Pharmacological chaperoning to stabilize misfolded enzymes and promote lysosomal trafficking, substrate reduction therapy to inhibit the synthesis of GM2 gangliosides, and enzyme replacement or gene therapy to restore catalytic activity.